PT Diagnos Laboratorium Utama Tbk (IDX:DGNS)

Indonesia · Delayed Price · Currency is IDR

234.00

-10.00 (-4.10%)

Jun 22, 2026, 11:46 AM WIB

49.04% (1Y)

Market Cap	305.00B +49.7%
Revenue (ttm)	171.06B +7.9%
Net Income	3.35B
EPS	2.68
Shares Out	1.25B
PE Ratio	91.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,874,600
Open	246.00
Previous Close	244.00
Day's Range	230.00 - 246.00
52-Week Range	136.00 - 382.00
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About IDX:DGNS

PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, body fluids, feces, specific proteins, DNAnswer genomics, kidney function, liver function, immunology, osteoporosis, thyroid, pharmacogenomic, heart, reproduction and fertility, microbiology,... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2007

Employees 81

Stock Exchange Indonesia Stock Exchange

Ticker Symbol DGNS

Full Company Profile

Financial Performance

In 2025, IDX:DGNS's revenue was 166.62 billion, an increase of 2.18% compared to the previous year's 163.07 billion. Earnings were 2.94 billion, an increase of 292.95%.

Financial Statements